Veritas To Market Epistem’s Services in Japan

Veritas Corp. has entered into an agreement with to market and distribute Epistem’s scientific research services in Japan. Epistem’s contract research division, located in Manchester England, provides specialized preclinical and scientific research services to drug development and personal care companies in the areas of oncology, mucositis, inflammatory bowel disease, wound healing and skincare. Epistem has a customer base in western Europe and the U.S and the Veritas agreement will provide a sales and marketing presence in Japan.

Epistem’s chief executive officer, Matthew Walls, said, “We are delighted to be working with Veritas. They have a strong scientific sales team and established distribution network. The Japanese drug development market provides us with an important opportunity for growth and the agreement with Veritas will allow us to develop closer links with existing Japanese customers.”

Sinsaku Iida, Veritas’ chief executive officer, said, ”It is our great pleasure to work with Epistem. Epistem’s Contract Research Division has a strong preclinical and scientific research service capability, which will benefit Japanese pharmaceutical and personal care companies. Veritas’ sales network has the scientific experience necessary to introduce Epistem’s high quality services to potential Japanese customers and will make for more efficient marketing and easier access for Japanese customers to Epistem.“